Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Turning point therapeutics, inc. save search
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
ZLAB | News | $14.2 3.5% 3.38% 690K
|
Health Technology
|
| O: 2.31%
H: 10.14%
C: 8.87%
granted tumors treatment designation china therapy
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
ZLAB | News | $14.2 3.5% 3.38% 690K
|
Health Technology
|
| O: -1.12%
H: 1.1%
C: 0.38%
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Published: 2022-04-28 (Crawled : 21:00) - globenewswire.com
ZLAB | News | $14.2 3.5% 3.38% 690K
|
Health Technology
|
| O: 0.54%
H: 1.33%
C: -7.14%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 2.89%
H: 0.0%
C: -3.26%
topline therapeutics china phase 1
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
Published: 2022-04-12 (Crawled : 21:00) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 6.13%
H: 26.26%
C: 17.9%
topline therapeutics review positive phase 1
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
Published: 2022-03-21 (Crawled : 13:30) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -2.48%
H: 1.22%
C: -5.25%
pos enroll therapeutics positive
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted grant designation
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
ZLAB | News | $14.2 3.5% 3.38% 690K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted designation
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
Published: 2021-01-29 (Crawled : 14:00) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 3.99%
H: 3.22%
C: -0.01%
positive cancer phase 2 lung cancer
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Published: 2020-12-08 (Crawled : 22:00) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy treatment designation
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
Published: 2020-12-08 (Crawled : 14:02) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy tyrosine kinase inhibitor designation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.